Company / Operating Cash Flow per Share
Myriad Genetics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$0.02
FY2025
5-year range
-$1.47 / $0.26
FY2021-FY2025
Trend
+120.4%
vs FY2024
Sector context
#73 of 212
Health Care
What the data says
At $0.02, Myriad Genetics, Inc.'s operating cash flow per share ranks #73 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-1.47 in FY2023 to $2.06 in FY2016.
Based on SEC 10-K filings.
0.02 in FY2025 with a 5-year CAGR of -52.2%.
Improved from $-1.47 to $0.02 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -52.2%
- 10-Year CAGR
- -
Sector benchmark
#73 of 212 in Health CareTop 34% of 212This company $0.02 Sector average $5.28
▼
-99.6% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 120.4% year-over-year.
- Ranks #73 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2016.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.02 | +120.4% |
| FY2024 | -$0.11 | +92.6% |
| FY2023 | -$1.47 | -1.7% |
| FY2022 | -$1.45 | -649.0% |
| FY2021 | $0.26 | -70.3% |
| FY2020 | $0.89 | -42.3% |
| FY2019 | $1.54 | -8.6% |
| FY2018 | $1.68 | +16.4% |
| FY2017 | $1.44 | -30.0% |
| FY2016 | $2.06 | +21.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026